The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026, for adults with stage II/III locally ...
Among patients with bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) who achieved a complete response (CR) with nogapendekin alfa ...
Alongside urinary symptoms, the regimen can cause systemic effects such as chills, fever, and musculoskeletal pain. Eppie ...
Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS ...
NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and ...
Oral vitamin C at 1000 mg daily for 12 months did not slow clonal growth in adults with clonal cytopenia of undetermined ...
Please check back later for more content.
The U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) on October 7, ...
For MBC Awareness Day, an NP and a former ICU nurse living with metastatic breast cancer discuss repeat education, biomarker ...
Throughout treatment and survivorship, patients may experience fatigue, anxiety, changes in physical functioning, loss of confidence, isolation, and difficulty adjusting. As healthcare professionals ...
Breast cancer survivors are increasingly asking their care teams about glucagon-like peptide-1 (GLP-1) receptor agonists, and two nurses at Winship Cancer Institute of Emory University say the most ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results